
HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma

Grant Award Details

HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma

Grant Type: Therapeutic Translational Research Projects

Grant Number: TRAN1-12250

Investigator:

Name:	Lili Yang
Institution:	University of California, Los Angeles
Type:	PI

Disease Focus: Blood Cancer, Cancer, Multiple Myeloma

Human Stem Cell Use: Adult Stem Cell

Award Value: \$5,949,651

Status: Pre-Active

Grant Application Details

Application Title: HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma

Public Abstract:**Translational Candidate**

stem cell-based off-the-shelf CAR-iNKT cells

Area of Impact

multiple myeloma (MM)

Mechanism of Action

The proposed therapeutic candidate can directly kill MM tumor cells.

Unmet Medical Need

MM remains an incurable disease, with a high relapse rate. The proposed therapeutic candidate can offer a new treatment opportunity for a broad base of MM patients.

Project Objective

Pre-IND meeting with the FDA

Major Proposed Activities

- Pharmacology study of the therapeutic candidate
- Chemistry/Manufacturing/Control (CMC) study of the therapeutic candidate
- Safety study of the therapeutic candidate

Statement of Benefit to California:

In 2021 alone, it is estimated that over 3,320 Californians will be diagnosed with MM, and over 1,250 Californians will die of this disease. MM results in devastating economic impacts to the state of California, in addition to the substantial economic and emotional impacts on individual patients and their families. The proposed therapeutic candidate can potentially become a life-saving treatment for MM patients and therefore benefit the state of California.

Source URL: <https://www.cirm.ca.gov/our-progress/awards/hsc-engineered-shelf-car-inkt-cell-therapy-multiple-myeloma>